Literature DB >> 21713412

Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.

M Kristen Demoruelle1, Kevin Deane.   

Abstract

Antibodies to citrullinated protein antigens (ACPAs) are highly specific for rheumatoid arthritis (RA) and are useful in the diagnosis of RA as well as the prediction of the course and outcomes of disease. Multiple methodologies exist for measuring ACPAs, including the widely available tests for anticyclic citrullinated peptide antibodies and for antibodies to mutated/modified citrullinated vimentin. These methodologies overall have similar diagnostic accuracies for RA, although there is some variability. The discovery of ACPAs and the biology of citrullination have also led to important advances in the understanding of the pathophysiology and development of RA, especially regarding the relationship between potential genetic and environmental risk factors for RA. Going forward, research into autoimmunity to citrullinated proteins may help identify the specific etiology of RA and provide approaches for the prediction of future risk of disease, and ultimately prevention of RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21713412      PMCID: PMC4095867          DOI: 10.1007/s11926-011-0193-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  70 in total

Review 1.  Immunity to citrullinated proteins in rheumatoid arthritis.

Authors:  Lars Klareskog; Johan Rönnelid; Karin Lundberg; Leonid Padyukov; Lars Alfredsson
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

2.  Anti-cyclic citrullinated peptide antibody in systemic sclerosis.

Authors:  Y Morita; Y Muro; K Sugiura; Y Tomita
Journal:  Clin Exp Rheumatol       Date:  2008 Jul-Aug       Impact factor: 4.473

3.  A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.

Authors:  Mittermayer Santiago; Murray Baron; Kiyomitsu Miyachi; Marvin J Fritzler; M Abu-Hakima; S Leclercq; M Bell; M Hudson; J-P Mathieu; S Taillefer; N Jones; P Docherty; M Khraishi; J Markland; J Pope; D Robinson; D Smith; E Sutton
Journal:  Clin Rheumatol       Date:  2007-06-15       Impact factor: 2.980

4.  Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.

Authors:  Cornelia F Allaart; Ferdinand C Breedveld; Ben A C Dijkmans
Journal:  J Rheumatol Suppl       Date:  2007-11

5.  Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making.

Authors:  Annette H M van der Helm-van Mil; Jacqueline Detert; Saskia le Cessie; Andrew Filer; Hans Bastian; Gerd R Burmester; Tom W J Huizinga; Karim Raza
Journal:  Arthritis Rheum       Date:  2008-08

6.  Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis.

Authors:  K P Liao; K L Batra; L Chibnik; P H Schur; K H Costenbader
Journal:  Ann Rheum Dis       Date:  2008-01-30       Impact factor: 19.103

7.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.

Authors:  Henrike van Dongen; Jill van Aken; Leroy R Lard; Karen Visser; H Karel Ronday; Harry M J Hulsmans; Irene Speyer; Marie-Louise Westedt; André J Peeters; Cornelia F Allaart; René E M Toes; Ferdinand C Breedveld; Tom W J Huizinga
Journal:  Arthritis Rheum       Date:  2007-05

8.  Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis.

Authors:  D S Majka; K D Deane; L A Parrish; A A Lazar; A E Barón; C W Walker; M V Rubertone; W R Gilliland; J M Norris; V M Holers
Journal:  Ann Rheum Dis       Date:  2007-11-01       Impact factor: 19.103

9.  Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide.

Authors:  Prasanthi Kakumanu; Hajime Yamagata; Eric S Sobel; Westley H Reeves; Edward K L Chan; Minoru Satoh
Journal:  Arthritis Rheum       Date:  2008-06

10.  Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice.

Authors:  Jonathan A Hill; David A Bell; William Brintnell; David Yue; Bret Wehrli; Anthony M Jevnikar; David M Lee; Wolfgang Hueber; William H Robinson; Ewa Cairns
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

View more
  26 in total

1.  Socioeconomic disparities in the health of african americans with rheumatoid arthritis from the southeastern United States.

Authors:  Antoine R Baldassari; Rebecca J Cleveland; Beth L Jonas; Doyt L Conn; Larry W Moreland; S Louis Bridges; Leigh F Callahan
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

2.  The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.

Authors:  Daniela Josabeth López-Cano; Daniel Cadena-Sandoval; Olga Beltrán-Ramírez; Rosa Elda Barbosa-Cobos; Fausto Sánchez-Muñoz; Luis Manuel Amezcua-Guerra; Yaneli Juárez-Vicuña; María Concepción Aguilera-Cartas; José Moreno; Jesús Bautista-Olvera; Guillermo Valencia-Pacheco; Ricardo F López-Villanueva; Julian Ramírez-Bello
Journal:  Inflamm Res       Date:  2017-05-12       Impact factor: 4.575

Review 3.  Environmental and gene-environment interactions and risk of rheumatoid arthritis.

Authors:  Elizabeth W Karlson; Kevin Deane
Journal:  Rheum Dis Clin North Am       Date:  2012-05-30       Impact factor: 2.670

Review 4.  Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention.

Authors:  Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2018-06-26       Impact factor: 4.592

5.  Citrullination of NF-κB p65 promotes its nuclear localization and TLR-induced expression of IL-1β and TNFα.

Authors:  Bo Sun; Nishant Dwivedi; Tyler J Bechtel; Janet L Paulsen; Aaron Muth; Mandar Bawadekar; Gang Li; Paul R Thompson; Miriam A Shelef; Celia A Schiffer; Eranthie Weerapana; I-Cheng Ho
Journal:  Sci Immunol       Date:  2017-06-09

6.  Reciprocal regulation of Th2 and Th17 cells by PAD2-mediated citrullination.

Authors:  Bo Sun; Hui-Hsin Chang; Ari Salinger; Beverly Tomita; Mandar Bawadekar; Caitlyn L Holmes; Miriam A Shelef; Eranthie Weerapana; Paul R Thompson; I-Cheng Ho
Journal:  JCI Insight       Date:  2019-11-14

Review 7.  Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis.

Authors:  V Michael Holers
Journal:  Curr Opin Immunol       Date:  2013-11-08       Impact factor: 7.486

8.  Label-free detection of immune complexes with myeloid cells.

Authors:  Z Szittner; A E H Bentlage; P Rovero; P Migliorini; V Lóránd; J Prechl; G Vidarsson
Journal:  Clin Exp Immunol       Date:  2016-05-12       Impact factor: 4.330

9.  The functional PTPN22 C1858T polymorphism confers risk for rheumatoid arthritis in patients from Central Mexico.

Authors:  J F Mendoza Rincón; D López Cano; S Jiménez Morales; M L Rivas Jiménez; R E Barbosa Cobos; J Ramírez Bello
Journal:  Clin Rheumatol       Date:  2016-03-07       Impact factor: 2.980

10.  Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease.

Authors:  M Kristen Demoruelle; Mark C Parish; Lezlie A Derber; Jason R Kolfenbach; Jan M Hughes-Austin; Michael H Weisman; William Gilliland; Jess D Edison; Jane H Buckner; Ted R Mikuls; James R O'Dell; Richard M Keating; Peter K Gregersen; Jill M Norris; V Michael Holers; Kevin D Deane
Journal:  Arthritis Rheum       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.